NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis $10.26 -0.18 (-1.72%) Closing price 04:00 PM EasternExtended Trading$10.26 0.00 (0.00%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Dynavax Technologies Stock (NASDAQ:DVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dynavax Technologies alerts:Sign Up Key Stats Today's Range$10.20▼$10.4350-Day Range$9.77▼$11.3652-Week Range$9.22▼$14.63Volume1.57 million shsAverage Volume1.80 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$24.33Consensus RatingModerate Buy Company Overview Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. Read More Dynavax Technologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreDVAX MarketRank™: Dynavax Technologies scored higher than 94% of companies evaluated by MarketBeat, and ranked 77th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingDynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDynavax Technologies has only been the subject of 1 research reports in the past 90 days.Read more about Dynavax Technologies' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth53.13% Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is -22.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is -22.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dynavax Technologies' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.97% of the float of Dynavax Technologies has been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Dynavax Technologies has recently decreased by 4.42%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.59 Percentage of Shares Shorted12.97% of the float of Dynavax Technologies has been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Dynavax Technologies has recently decreased by 4.42%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News Sentiment1.03 News SentimentDynavax Technologies has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Dynavax Technologies this week, compared to 6 articles on an average week.Search Interest1 people have searched for DVAX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $41,116.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dynavax Technologies' insider trading history. Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DVAX Stock News HeadlinesDynavax Technologies (NASDAQ:DVAX) Director Acquires $41,116.00 in StockAugust 26 at 5:07 AM | insidertrades.comDynavax to Participate in the 2025 Wells Fargo Healthcare Conference5 hours ago | prnewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.August 27 at 2:00 AM | Traders Agency (Ad)Insider Buying: Scott Myers Acquires Shares of Dynavax Technologies Corp (DVAX)August 25 at 11:31 AM | gurufocus.comDynavax Technologies (NASDAQ:DVAX) Receives "Market Outperform" Rating from JMP SecuritiesAugust 24 at 2:37 AM | americanbankingnews.comDynavax Technologies Stock (DVAX) Opinions on Shingles Vaccine Trial ResultsAugust 23, 2025 | quiverquant.comQDynavax Technologies (DVAX) Receives Reiteration of 'Market Outperform' Rating | DVAX Stock NewsAugust 22, 2025 | gurufocus.comDynavax shares jump 8% after promising shingles vaccine trial resultsAugust 22, 2025 | msn.comSee More Headlines DVAX Stock Analysis - Frequently Asked Questions How have DVAX shares performed this year? Dynavax Technologies' stock was trading at $12.77 at the beginning of the year. Since then, DVAX stock has decreased by 19.7% and is now trading at $10.26. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Corporation (NASDAQ:DVAX) released its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.02. The biopharmaceutical company earned $95.44 million during the quarter, compared to the consensus estimate of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive trailing twelve-month return on equity of 5.10%. Read the conference call transcript. Who are Dynavax Technologies' major shareholders? Dynavax Technologies' top institutional shareholders include State Street Corp (5.45%), Chicago Capital LLC (4.35%), Geode Capital Management LLC (2.24%) and Blair William & Co. IL (1.90%). Insiders that own company stock include Andrew A F Hack, Robert Janssen, Francis Cano, Scott Dunseth Myers, David F Novack and Justin Burgess. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/07/2025Today8/27/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees350Year Founded1996Price Target and Rating Average Price Target for Dynavax Technologies$24.33 High Price Target$32.00 Low Price Target$10.00 Potential Upside/Downside+137.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E Ratio32.06 P/E GrowthN/ANet Income$27.31 million Net Margins-16.67% Pretax Margin-15.56% Return on Equity5.10% Return on Assets3.00% Debt Debt-to-Equity Ratio0.45 Current Ratio6.65 Quick Ratio6.01 Sales & Book Value Annual Sales$316.27 million Price / Sales3.80 Cash Flow$0.16 per share Price / Cash Flow65.61 Book Value$4.21 per share Price / Book2.44Miscellaneous Outstanding Shares117,267,000Free Float113,772,000Market Cap$1.20 billion OptionableOptionable Beta1.09 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DVAX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.